Skip to main content

Advertisement

SpringerLink
Log in

Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the acute effects of sildenafil (50 mg) on the micturation of men with erectile dysfunction (ED) and concomitant benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) using uroflowmetric parameters.

Materials and methods

A total of 68 male patients randomized into two groups (36 treatment, 32 control groups) with International Prostate Symptom Score (IPSS) greater than 7 and International Index of Erectile Dysfunction-erectile function domain score lower than 26 were enrolled in the study. Patients in the treatment group received a single dose of 50 mg of oral sildenafil. Patients in the control group received no treatment. Prevoiding urine volumes determined ultrasonographically and voided urine volumes were also recorded. Statistical comparisons were made with the use of analysis of variance (ANOVA).

Results

Mean ages were similar between treatment and control groups (60.4 ± 9.8 and 58.6 ± 8.3 years, respectively, P = 0.430). In the treatment group the maximum and average flow rates increased significantly (Q max from 15.6 ± 6.8 cc/s to 19.3 ± 7.2 cc/s, P < 0.0001; Q avg from 7.3 ± 3.0 cc/s to 9.1 ± 3.0 cc/s, P < 0.0001) with sildenafil administration, while other parameters studied remained unchanged.

Conclusion

Despite the limitations of variations of uroflowmetry, this study showed that sildenafil improves Q max and Q avg in patients suffering from ED with concomitant BPH-LUTS. Long-term studies are needed to evaluate the effects on IPSS, side effects, and drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Emgelmann U (2003) Epidemiology of erectile dysfunction: Results of the “Cologne Male Survey”. Int J Impot Res 15:63–71. doi:10.1038/sj.ijir.3900949

    Article  CAS  Google Scholar 

  2. Mulhall JP, Guhring P, Parker M, Hopps C (2006) Assessment of the effect of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3:662–667. doi:10.1111/j.1743-6109.2006.00259.x

    Article  PubMed  CAS  Google Scholar 

  3. Ponholzer A, Temml C, Obermayr R, Madersbacher S (2004) Association between lower urinary tract symptoms and erectile dysfunction. Urology 64(4):772–776. doi:10.1016/j.urology.2004.05.025

    Article  PubMed  Google Scholar 

  4. Mc Vary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomised double blind trial. J Urol 177:1071–1077. doi:10.1016/j.juro.2006.10.055

    Article  CAS  Google Scholar 

  5. Mc Vary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM et al (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177:1401–1407. doi:10.1016/j.juro.2006.11.037

    Article  CAS  Google Scholar 

  6. Kaplan AS, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723. doi:10.1016/j.eururo.2007.01.033

    Article  PubMed  CAS  Google Scholar 

  7. Andersson KE, Uckert S, Stief C, Hedlund P (2007) Phosphodiesterases and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 26:928–933. doi:10.1002/nau.20485

    Article  PubMed  CAS  Google Scholar 

  8. Kaplan AS, Gonzales RR (2007) Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 9(2):73–77

    PubMed  Google Scholar 

  9. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P (2006) Per-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98:1259–1263. doi:10.1111/j.1464-410X.2006.06501.x

    Article  PubMed  CAS  Google Scholar 

  10. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M et al (2007) Characterization and functional role of an androgen-dependent PDE5 activity in bladder. Endocrinology 148(3):1019–1029. doi:10.1210/en.2006-1079

    Article  PubMed  CAS  Google Scholar 

  11. Ückert S, Küthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166:2484–2490. doi:10.1016/S0022-5347(05)65621-2

    Article  PubMed  Google Scholar 

  12. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H (1995) Effects of nitric oxide on human and canine prostates. Urology 45(3):440–446. doi:10.1016/S0090-4295(99)80013-2

    Article  PubMed  CAS  Google Scholar 

  13. Malavaud B, Rostaign L, Tran-Van T, Tack I, Ader JL (2001) Transient renal effects of sildenafil in male kidney transplantation recipients. Transplantation 72(7):1331–1333. doi:10.1097/00007890-200110150-00027

    Article  PubMed  CAS  Google Scholar 

  14. Rostaign L, Tran-Van T, Ader JL (2000) Increased glomerular filtration rate in kidney transplant recipients who take sildenafil. N Engl J Med 342(22):1679–1680. doi:10.1056/NEJM200006013422217

    Article  Google Scholar 

  15. Sairam K, Kulinskaya E, Mcnicholas TA, Boustead GB, Hanbury DC (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90:836–839. doi:10.1046/j.1464-410X.2002.03040.x

    Article  PubMed  CAS  Google Scholar 

  16. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH (2003) Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical “Aging Male” symptoms? Results of the “Cologne Male Survey”. Eur Urol 44:588–594. doi:10.1016/S0302-2838(03)00358-0

    Article  PubMed  CAS  Google Scholar 

  17. Chang S, Hypolite JA, Zderic SA, Wein AJ, Chacko S, DiSanto ME (2002) Enhanced force generation by corpus cavernosum smooth muscle in rabbits with partial bladder outlet obstruction. J Urol 167:2636–2644. doi:10.1016/S0022-5347(05)65050-1

    Article  PubMed  CAS  Google Scholar 

  18. Hiebele JP, Ruffolo RR Jr (1996) The use of alpha adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res 33:145–160. doi:10.1006/phrs.1996.0022

    Article  Google Scholar 

  19. Gingell C, Sultana SR, Wulf MB, Gepi-Attee S (2004) Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 1:179–184. doi:10.1111/j.1743-6109.2004.04026.x

    Article  PubMed  CAS  Google Scholar 

  20. Cook AL, Haynes JM (2004) Protein kinase G-II mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 16:253–261. doi:10.1016/S0898-6568(03)00134-7

    Article  PubMed  CAS  Google Scholar 

  21. Adolfsson PL, Ahlstrand C, Varenhorst E, Svensson SP (2002) Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverine generate inhibition. Prostate 51:50–58. doi:10.1002/pros.10077

    Article  PubMed  CAS  Google Scholar 

  22. Qiu Y, Kraft P, Carig EC, Liu X, Haynes-Johnson D (2002) Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 59:145–149. doi:10.1016/S0090-4295(01)01471-6

    Article  PubMed  Google Scholar 

  23. Haaga JR, Exner A, Fei B, Seftel A (2007) Semiquantitative imaging measurement of baseline and vasomodulated normal prostatic blood flow using sildenafil. Int J Impot Res 19(1):110–113. doi:10.1038/sj.ijir.3901486

    Article  PubMed  CAS  Google Scholar 

  24. Rashid A (2005) The efficacy and safety of PDE5 inhibitors. Clin Cornerstone Int 7(1):47–56. doi:10.1016/S1098-3597(05)80048-1

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Department, Mustafa Kemal University, Hatay, Turkey

    Esref O. Guven & Mevlana D. Balbay

  2. Gülhane Military Medical Academy, Ankara, Turkey

    Kilciler Mete

  3. Urology Department, Ankara Atatürk Research Hospital, Ankara, Turkey

    Ege C. Serefoglu

Authors
  1. Esref O. Guven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mevlana D. Balbay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kilciler Mete
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ege C. Serefoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esref O. Guven.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guven, E.O., Balbay, M.D., Mete, K. et al. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol 41, 287–292 (2009). https://doi.org/10.1007/s11255-008-9423-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-008-9423-y

Keywords

Search

Navigation